Migraine Therapeutic Market

Migraine is a neurological disorder often described as intense pulsing or throbbing pain in one area of the head. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. Migraines are a type of headache that tend to cause other signs and symptoms, too, such as nausea and vision problems. There’s no cure for migraines yet, but medicines can help prevent or stop them, or keep signs and symptoms from getting worse.

Market Dynamics:

Increase in prevalence of migraine, increase in demand for safe and effective treatment, increase in awareness about migraine and its treatment options, and rise in research and development across the world are major factors expected to propel the growth of the global migraine therapeutic market during the forecast period. For instance, migraine is a serious and common neurological condition with a serious impact on quality of life. In 2020, migraine has been ranked by WHO as the most prevalent neurological condition causing the highest loss of years due to disability.

In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.

Key features of the study:

• This report provides in-depth analysis of the global migraine therapeutic market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global migraine therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Amgen Inc., Allergan Inc., Bausch Health Companies Inc., and Teva Pharmaceutical Industries Ltd., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global migraine therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global migraine therapeutic market.

Detailed Segmentation:

• Global Migraine Therapeutic Market, By Therapeutics:
  • Pain-relieving Medications
  • Preventive Medications
• Global Migraine Therapeutic Market, By Route of Administration:
  • Oral and Nasal
  • Injection
• Global Migraine Therapeutic Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Middle East 
  • Africa
  • Latin America
• Company Profiles:
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Amgen Inc.
  • Allergan Inc.
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd.